Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IDNA vs IHAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IHAK Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

IHAK Overall Winner 6-Pillar Tally: IDNA 0 – 0 IHAK (6 Tie) Matrix Metrics: IDNA 1 – 2 IHAK

As of Nov 16, 2026, iShares Cybersecurity and Tech ETF (IHAK) is the stronger overall head-to-head candidate over iShares Genomics Immunology and Healthcare ETF (IDNA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IDNA carries a Unified Composite Score of 41.7/100 (SELL) at $39.25 (N/M Forward P/E, N/A operating margin), whereas IHAK carries 55.0/100 (HOLD) at $67.66 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IDNA vs IHAK
IDNA NYSE Arca
iShares Genomics Immunology and Healthcare ETF
Institutional Equity
$39.25
-2.12% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.17β · 44% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 28.0 Fund 33.0 Flow 50.0 Mom 21.8
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.3 · SMA20: $42.01 · SMA50: $41.21
IHAK NYSE Arca Head-to-Head Winner
iShares Cybersecurity and Tech ETF
Institutional Equity
$67.66
-0.46% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 39% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 58.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.9 · SMA20: $70.94 · SMA50: $68.89

6-Pillar Scorecard Institutional Category Breakdown (IDNA 0 – 0 IHAK)

Columns: Metric · IDNA · IHAK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 44.7% (20th %ile) 22.7% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IDNA (1) vs IHAK (2)
Institutional Metric IDNA IHAK Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
74% ($25–$44) 73% ($41–$78) Stronger Trend IDNA
Beta / 30D Volatility
Risk Regime
1.17β · 44% Vol 1.05β · 39% Vol Lower Realized Risk IHAK
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 55.0 / 100 (HOLD) Higher Composite IHAK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IHAK +4.62 pp
IDNA: -3.18% · IHAK: +1.44%
3M Horizon IDNA +5.51 pp
IDNA: +9.09% · IHAK: +3.58%
6M Horizon IDNA +11.41 pp
IDNA: +37.62% · IHAK: +26.21%
1Y Horizon IDNA +17.98 pp
IDNA: +51.96% · IHAK: +33.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IDNA vs IHAK. Trailing 12-month operating profitability (IDNA N/A vs IHAK N/A) and valuation multiples (IDNA N/M vs IHAK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IDNA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
IHAK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IDNA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 44.7%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IDNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IHAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.7%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IHAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IDNA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IHAK Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IDNA vs IHAK Key Questions & Quantitative Answers

As of Nov 16, 2026, iShares Cybersecurity and Tech ETF (IHAK) is the stronger overall head-to-head candidate over iShares Genomics Immunology and Healthcare ETF (IDNA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IDNA carries a Unified Composite Score of 41.7/100 (SELL) at $39.25 (N/M Forward P/E, N/A operating margin), whereas IHAK carries 55.0/100 (HOLD) at $67.66 (N/M Forward P/E, N/A operating margin). Technically, IDNA sits in a Neutral phase (RSI 41.3, UNCLASSIFIED options structure) and IHAK sits in a Neutral phase (RSI 44.9, UNCLASSIFIED options structure).

IDNA and IHAK split Growth & Scale metrics: IDNA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IHAK at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, IDNA generates N/A in USD-normalized revenue versus N/A for IHAK. In operating R&D and SG&A reinvestment, IDNA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IHAK.

IDNA and IHAK trade at balanced relative valuation multiples. IDNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IHAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IDNA (N/A ROE) versus IHAK (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, IDNA carries 44.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.17β · 44% Vol realized risk). By comparison, IHAK carries 22.7% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.